Cell-bound complement activation products

Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway. They appear potentially useful for the diagnosis of systemic lupus erythematosus as of 2015.

Medical use

CB-CAPs can be used in the diagnosis and monitoring of SLE. Their efficacy is aided by the ability to be measured throughout the lifespans of erythrocytes, b-lymphocytes.

Research

Research into the development of CB-CAPs has been advocated by the Lupus Foundation of America.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1316685770 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001316685770 · captured 2025-10-13 · not yet sealed in the ledger · verify the chain · version history

Cite this page as: encyclopegia.org, “Cell-bound complement activation products”, snapshot enwiki-001316685770. https://encyclopegia.org/a/cell-bound-complement-activation-products

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.